| Full Name | Lori Arp |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 2325 S Harvard Ave, Tulsa, Oklahoma |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003245531 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 106764 (Oklahoma) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lori Arp, 650 S Peoria Ave, Tulsa, OK 74120-4429 Ph: (918) 587-9471 | Lori Arp, 2325 S Harvard Ave, Tulsa, OK 74114-3300 Ph: (918) 712-4301 |
News Archive
Derycz Scientific, Inc., the content repurposing company, today announced that its subsidiary Reprints Desk, an award-winning provider of information services and content workflow solutions, has launched ePrints NRx, a new scientific article collection service that simplifies the re-use of PDFs by medical marketers, brand managers and sales professionals.
A comprehensive characterization of the immune responses between SARS-CoV-2 infected individuals with wildtype (WT) and Δ382 SARS-CoV-2.
Faculty at Louisiana Tech University have discovered, for the first time, a new nanocomposite formed by the self-assembly of copper and a biological component that occurs under physiological conditions, which are similar those found in the human body and could be used in targeted drug delivery for fighting diseases such as cancer.
Nature News reports on last week's announcement of preliminary results from a large clinical trial testing the efficacy of GlaxoSmithKline's (GSK) RTS,S malaria vaccine, writing that while media coverage of the announcement touted it as a "big breakthrough in the long campaign to create a malaria vaccine," "several leading vaccine researchers, who are critical of the unusual decision to publish partial trial data, argue that the results raise questions about whether the RTS,S/AS01 candidate vaccine can actually win approval."
Eisai Corporation of North America has announced data from a Phase II trial evaluating a five-day dosing regimen of Dacogen(R) (decitabine for injection) in acute myeloid leukemia (AML), the most common form of leukemia.
› Verified 6 days ago
Sara Theriac, APRN-CNP Registered Nurse Medicare: Medicare Enrolled Practice Location: 1055 S Houston Ave, Tulsa, OK 74127 Phone: 918-921-3200 | |
Kassidy Jade Murohy, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 2325 S Harvard Ave, Tulsa, OK 74114 Phone: 209-588-6948 | |
Tanya Crawford, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 6333 E Skelly Dr, Tulsa, OK 74135 Phone: 918-664-4224 | |
Madison Colclazier, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 6128 E 38th St, Tulsa, OK 74135 Phone: 539-240-7461 | |
Taylor L Claybrook, MSN, RN Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 1705 E 19th St # St302, Tulsa, OK 74104 Phone: 918-748-7599 | |
Mrs. Caitlyn Rayann Brannon, RN, MSN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1717b S Utica Ave Ste 205, Tulsa, OK 74104 Phone: 918-744-2444 |